This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail.
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed its acquisition of Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment.
UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the UK Competition and Markets Authority (the “CMA”) has unconditionally approved the previously announced tender offer (the “Offer”) by Orion Acquisition AB (the “Buyer”), a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher” or “Parent”), for all outstanding Common Shares and American Depositary Shares (together, the “Shares”) of Olink for $26.00 per Share.
UPPSALA, Sweden, July 05, 2024 (GLOBE NEWSWIRE) -- At the Extra General Meeting (the “EGM”) of Olink Holding AB (publ), reg. no 559189-7755, (the “Company”), the EGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the EGM and the complete proposals, which have previously been published and are available on the Company’s website, www.olink.com.
UPPSALA, Sweden, July 03, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK), a global leader in proteomics, introduces its inaugural network of Olink® Certified Service Providers. The group of Olink Certified Service Providers represent leading contract research organizations (CROs) and service labs around the world.
This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail.
UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research.
UPPSALA, Sweden, May 30, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers.
UPPSALA, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter ended March 31, 2024.
UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the “AGM”) of Olink Holding AB (publ), reg. no 559189-7755, (the “Company”), on 19 April 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company’s website, www.olink.com.
UPPSALA, Sweden, April 02, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the availability of an open access data library consisting of over 300,000 protein-disease risk associations, giving researchers a powerful new tool for revealing the biological mechanisms underlying 106 human diseases.
UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2023 is now available on the Company’s website at https://investors.olink.com/.
UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023.
UPPSALA, Sweden, March 15, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg. no. 559189-7755, are hereby given notice to attend the Annual General Meeting to be held at 4:00 p.m. CET on Friday the 19 April 2024, in the Company’s facilities at Salagatan 16A, Uppsala. Registration for the meeting commences at 3:30 p.m. CET.
UPPSALA, Sweden, March 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Olink’s 2024 Annual General Meeting (“AGM”) will be held in Uppsala, Sweden on April 19th, 2024. The AGM was previously scheduled to take place on April 17th, 2024.
UPPSALA, Sweden, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the third quarter ended September 30, 2023.
UPPSALA, Sweden, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that Novogene Asia Pacific Middle East and Africa (AMEA) has adopted the Olink Explore HT platform to deliver advanced next-generation proteomics technology to the scientific community in the region.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Olink Holding AB (publ) (NasdaqGS: OLK) to Thermo Fisher Scientific Inc. (NYSE: TMO). Under the terms of the proposed transaction, shareholders of Olink will receive $26.00 in cash for each common share of Olink that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
